Ageing research reviews最新文献

{"title":"Oxidative Stress and Mitochondrial Impairment: Key Drivers in Neurodegenerative Disorders.","authors":"Pei Wen, Zhixin Sun, Fengting Gou, Jingjing Wang, Qing Fan, Deming Zhao, Lifeng Yang","doi":"10.1016/j.arr.2025.102667","DOIUrl":"https://doi.org/10.1016/j.arr.2025.102667","url":null,"abstract":"<p><p>Mitochondrial dysfunction and oxidative stress are critical factors in the pathogenesis of neurodegenerative diseases. The complex interplay between these factors exacerbates neuronal damage and accelerates disease progression. In neurodegenerative diseases, mitochondrial dysfunction impairs ATP production and promotes the generation of reactive oxygen species (ROS). The accumulation of ROS further damages mitochondrial DNA, proteins, and lipids, creating a vicious cycle of oxidative stress and mitochondrial impairment. This review aims to elucidate the mechanisms by which mitochondrial dysfunction and oxidative stress lead to neurodegeneration, and to highlight potential therapeutic targets to mitigate their harmful effects.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":" ","pages":"102667"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving landscape of colorectal cancer: Global and regional burden, risk factor dynamics, and future scenarios (the Global Burden of Disease 1990-2050).","authors":"Jiajie Zhou, Qizhi Yang, Shuai Zhao, Longhe Sun, Ruiqi Li, Jie Wang, Liuhua Wang, Daorong Wang","doi":"10.1016/j.arr.2025.102666","DOIUrl":"10.1016/j.arr.2025.102666","url":null,"abstract":"<p><strong>Background: </strong>Presently, colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. We provided global, regional, and national estimates of the burden of CRC and their attributable risks from 1990 to 2021, aiming to guide screening, early detection, and treatment strategies, optimize healthcare resource allocation, and facilitate the rational management of burden of CRC.</p><p><strong>Methods: </strong>Using data derived from the Global Burden of Disease database, we estimated the incidence, mortality, and disability-adjusted life years (DALYs) of CRC. The temporal trends of the age-standardized rate of CRC were quantified by calculating the estimated annual percentage changes (EAPC). Deaths from CRC attributable to each risk factor that had evidence of causation with CRC were estimated. CRC's deaths and DALYs was forecast through 2050 by logistic regression with Socio-Demographic Index as a predictor, then multiplying by projected population estimates.</p><p><strong>Results: </strong>Globally, between 1990 and 2021, the incident cases, death cases, and DALYs attributed to CRC have doubled, the age-standardized incidence rate (ASIR) presented a slightly upward tendency, while the age-standardized death rate (ASMR) and the age-standardized DALYs rate (ASDR) exhibited a decreasing trend. From 1990-2021, the ASIR for males has an increased trend, while females presented a downward trend. The ASIR and ASDR of CRC were higher in high and high-middle sociodemographic index (SDI) countries. The ASIR of CRC in 165 countries and territories showed escalating trend. Globally, for males and both sexes combined, diet low in whole grains was the leading risk factor for age-standardized deaths from CRC in 2021. However, among females, diet low in milk was the leading risk factor. We forecast that 2.18 million (1.53-2.94) individuals will death for CRC worldwide by 2050, and the DALYs achieve 41.7 million (29.9-55.4) by 2050.</p><p><strong>Conclusion: </strong>The doubling of incidence counts and mortality cases and the rising ASIR in most countries indicates a significant burden of CRC. Authorities should devise suitable measures to address the increasing burdens, such as optimizing screening programs, enhancing awareness and screening efforts for males, and reducing exposure to modifiable risk factors.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":" ","pages":"102666"},"PeriodicalIF":0.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quercetin-functionalized nanomaterials: Innovative therapeutic avenues for Alzheimer's disease management.","authors":"Jinjin Pei, Ranil Vikraman Kumarasamy, Selvaraj Jayaraman, Gopalakrishnan Velliyur Kanniappan, Qianfa Long, Chella Perumal Palanisamy","doi":"10.1016/j.arr.2025.102665","DOIUrl":"10.1016/j.arr.2025.102665","url":null,"abstract":"<p><p>Alzheimer's Disease (AD) is a major global health challenge, largely due to its complex pathology and the limited effectiveness of existing treatments. Quercetin, a bioactive compound belonging to the flavonoid class, its promising antioxidant, anti-inflammatory, and neuroprotective effects in addressing AD. However, its therapeutic potential is hindered by challenges such as low bioavailability, instability, and restricted permeability across the blood-brain barrier (BBB). Advances in nanotechnology have paved the way for quercetin-functionalized nanomaterials, offering solutions to these challenges. These nanostructures enhance quercetin's solubility, stability, and targeted brain delivery, thereby augmenting its therapeutic potential. In this review, nanocarriers (like liposomes, polymeric nanoparticles, and metal-based nanosystems) are explored for their potential application in optimizing quercetin delivery in AD management. It discusses the mechanisms by which these nanostructures enhance BBB penetration and exert neuroprotective effects. Furthermore, the review examines the outcomes of preclinical and in vitro studies, while addressing the challenges of scaling these approaches for clinical application. By merging the fields of nanotechnology and neurotherapeutics, the importance of quercetin-functionalized nanomaterials in advancing AD management strategies is underscored in this review.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":" ","pages":"102665"},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can microbiota gut-brain axis reverse neurodegenerative disorders in human?","authors":"Yuan Xingxing, Serge Yannick Ouedraogo, Modou Lamin Jammeh, Lucette Simbiliyabo, John Nute Jabang, Mariam Jaw, Alansana Darboe, Yurong Tan, Ousman Bajinka","doi":"10.1016/j.arr.2025.102664","DOIUrl":"https://doi.org/10.1016/j.arr.2025.102664","url":null,"abstract":"<p><p>The trillions of microbial populations residing in the gut have recently shown that they can be used as a remedy for various diseases. The gut microbiota-brain-axis interface is one unique pathway that the microbiota demonstrates its medicinal value. This medicinal value is further seen when there is a decline in gut microbial diversity (dysbiosis). Dysbiosis leads to neurodegenerative disorders (NDDs). The objective of this review is to ascertain the clinical significance of gut microbiota induced therapeutic strategies. While navigating this important area of interest, we will elucidate the research gaps, the prospects and the potential reverse interventions of the studied NDDs. In addition to our previous work, relevant literature published in English were searched and retrieved from the PubMed database. The 'gut microbiota and Neurodegenerative disorders' were used as keywords during the search period. The Filters applied are: Abstract, Full text, Meta-Analysis, Randomized Controlled Trial, Reviews, in the last 5 years. The articles were analyzed in our unrelenting quest to make sense of the prospects and research gap in gut microbiota-brain-axis. This chapter is a result of this meticulous work. More convincing data from researches on gut microbiota-brain-axis are required to provide clinical significance including neuroimaging studies. Addressing the structural (pathological footprints) and the functional changes (diseases manifestation) involving gut microbiota-brain-axis require a holistic approach. While the pharmacological therapies such as chemotherapeutic and chemobiotic treatment approaches come with low success rates, non-pharmacological interventions are found to be more useful in reversing NDDs. The inability to detect NDDs at an early stage in their clinical history, makes preventive medicinal approaches the must needed and best intervention strategy. Gut-driven treatments have a lot to offer in the management of refractory neurologic diseases.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":" ","pages":"102664"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why are we not exploring the potential of lower limb muscle power to identify people with sarcopenia?","authors":"Hélio José Coelho-Júnior, Alejandro Álvarez-Bustos, Francesco Landi, Samuel da Silva Aguiar, Leocadio Rodriguez-Mañas, Emanuele Marzetti","doi":"10.1016/j.arr.2025.102662","DOIUrl":"https://doi.org/10.1016/j.arr.2025.102662","url":null,"abstract":"<p><p>Sarcopenia refers to a neuromuscular disease characterized by age-related declines in muscle mass and function. Since Professor Rosenberg first introduced the concept of sarcopenia in 1989, numerous operational paradigms have been proposed, tested, and validated against negative outcomes. The most recent recommendations advocate that dynapenia, or reduced of muscle strength, should be used alongside low muscle mass for the identification of sarcopenia. This approach is based on the understanding that impairments in muscle strength are a major consequence of muscle failure. However, empirical evidence has yielded conflicting results regarding the ability of current sarcopenia definitions to identify individuals at higher risk of adverse health-related events. Muscle power - the capacity to generate strength rapidly - has emerged as a critical domain of physical performance in old age. Not only does it decline earlier and more drastically than other measures (e.g., muscle strength), but it is also more strongly associated with adverse outcomes. In this view point, we provide an appraisal of muscle power as a more reliable indicator of muscle failure, compared with other measures (e.g., strength), for identifying individuals with sarcopenia in both geriatric and non-geriatric settings. We also discuss major challenges hindering the conduct of meaningful investigations on this subject.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":"104 ","pages":"102662"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of digital-based interventions on the outcomes of the eligibility criteria for sarcopenia in healthy older adults: A systematic review and meta-analysis.","authors":"Hyuma Makizako, Daijo Shiratsuchi, Shoma Akaida, Mana Tateishi, Keisuke Maeda, Katsuya Iijima, Hiroyuki Shimada, Tatsuro Inoue, Minoru Yamada, Ryo Momosaki, Hidetaka Wakabayashi, Koichi Yamamoto, Hidenori Arai","doi":"10.1016/j.arr.2025.102663","DOIUrl":"https://doi.org/10.1016/j.arr.2025.102663","url":null,"abstract":"<p><strong>Background: </strong>While the digital-based interventions targeting older adults to prevent age-related health problems such as sarcopenia have grown rapidly in recent years, there are no meta-analyses indicating synthesized pooled estimates.</p><p><strong>Objective: </strong>To examine the effects of digital-based interventions on sarcopenia-related measures, including physical performance and muscle mass, in healthy community-dwelling older adults.</p><p><strong>Methods: </strong>Systematic searches were performed on MEDLINE, Web of Science, and Cochrane Library for eligible studies published up to 31 March 2023. The mean difference with a 95 % confidence interval was calculated. Methodological quality was assessed using Cochrane RoB 2.0. The GRADE criteria were used to assess evidence certainty.</p><p><strong>Results: </strong>Thirteen randomized controlled trials with 742 participants were included in the meta-analysis. Handgrip strength, usual walking speed, five times sit-to-stand performance, and 30-second chair stand test showed significant enhancements with the digital-based interventions. However, there were no significant effects of digital-based interventions in appendicular muscle mass. The overall evidence certainty was low.</p><p><strong>Conclusions: </strong>Although digital-based interventions for healthy older adults are effective in improving physical functions, evidence certainty is low. Additional randomized controlled trials are thus required to further validate the findings.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":"104 ","pages":"102663"},"PeriodicalIF":0.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication reviews in hospitalised patients for reduced hospital readmission and mortality. Systematic review, meta-analysis and meta-regression of RCTs.","authors":"Miriam Degen, Li-Ju Chen, Ben Schöttker","doi":"10.1016/j.arr.2025.102661","DOIUrl":"10.1016/j.arr.2025.102661","url":null,"abstract":"<p><p>Efforts to reduce preventable medication-related harm through medication reviews have increased, but interventions often yield null-results regarding clinical outcomes. We conducted a systematic literature search in four data bases and summarised the available evidence from randomised controlled trials (RCTs) comparing medication reviews and usual care in hospitalised patients regarding hospital readmissions and all-cause mortality by random-effects meta-analyses. Effect size differences by methodological study differences were of special interest. The meta-analysis of all 24 trials on hospital readmissions, including 12,539 participants, showed a statistically significant 8 % decrease in hospital readmissions (risk ratio (RR) [95 % confidence interval]: (0.92 [0.88-0.97], p = 0.002). The number of patient contacts was the most prominent effect modifier in meta-regression (p = 0.003) and the effect of medication reviews was approximately twice as strong (15 %) in 11 trials with 2 or more patient contacts (0.85 [0.78-0.92], p < 0.001). No statistically significant reduction in all-cause mortality was observed in a meta-analysis of all 22 trials with data for this outcome (0.95 [0.86-1.04], p = 0.24), including 12,350 participants. The method of mortality assessment was identified as an effect modifier by meta-regression (p = 0.01). A meta-analysis of 10 trials with complete mortality ascertainment via registries or primary care data showed a significantly 19 % reduced mortality (0.81 [0.70-0.94], p < 0.01). In conclusion, medication reviews reduce the risk of hospital readmission and might also reduce all-cause mortality. Comprehensive mortality assessment was essential for successful trials. Clinical guidelines should recommend medication reviews with multiple patient contacts, involving pharmacists, either for repeated medication reviews or to improve adherence.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":" ","pages":"102661"},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging role of oxygen redox in pathological progression of disorders.","authors":"Shuang-Yu Li, Xue-Yan Gong, Ferdinand Ndikuryayo, Wen-Chao Yang","doi":"10.1016/j.arr.2025.102660","DOIUrl":"10.1016/j.arr.2025.102660","url":null,"abstract":"<p><p>Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington disease, pose serious threats to human health, leading to substantial economic burdens on society and families. Despite extensive research, the underlying mechanisms driving these diseases remain incompletely understood, impeding effective diagnosis and treatment. In recent years, growing evidence has highlighted the crucial role of oxidative stress in the pathogenesis of various neurodegenerative diseases. However, there is still a lack of comprehensive reviews that systematically summarize the impact of mitochondrial oxidative stress on neurodegenerative diseases. This review aims to address this gap by summarizing the molecular mechanisms by which mitochondrial oxidative stress promotes the initiation and progression of neurodegenerative disorders. Furthermore, it discusses the potential of antioxidant-based therapeutic strategies for the treatment of these diseases. By shedding light on the role of mitochondrial oxidative stress in neurodegenerative diseases, this review not only serves as a valuable reference for further research on the disease mechanisms, but also offers novel perspectives for the treatment of these disorders.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":" ","pages":"102660"},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twelve weeks of exercise training improves cognitive status, physical performance and quality of life in Alzheimer's disease: A systematic review and meta-analysis.","authors":"Cauã Viana Fernandes de Sá Leitão, Bernardo de Faria Moraes, Gabriel André Pedral Diniz Leite, Amanda Gonçalves Duarte, Marcos Vinícius Gonçalves da Silva, Gabriel Moraes de Oliveira, Fernando Augusto Barcelos Andrade, Jair Antônio Bessa da Silva, Renata Campos Correa Dos Santos, Gustavo Soares Figueiredo, Helton Oliveira Campos, Laura Hora Rios Leite, Lucas Rios Drummond, Cândido Celso Coimbra","doi":"10.1016/j.arr.2025.102655","DOIUrl":"10.1016/j.arr.2025.102655","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which there is slow and gradual impairment of mental function. Considering the increase in cases due to population aging, the potential benefits of physical training in AD are of great importance and need further elucidation. This study aims to identify the impact of physical training on crucial aspects of AD such as cognitive status, physical performances, quality of life and activities of daily living. The bibliographic research was conducted according to the guidelines outlined in PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis). After the selection process, 26 studies were included in the systematic review and meta-analysis. Physical training for up to 12 weeks had a moderate effect on the cognitive status (SMD: 0.34; 95 % CI: 0.07-0.61; p = 0.016), the physical performance (SMD: 0.75; 95 % CI: 0.43-1.06; p = 0.000) and the quality of life (SMD: 0.40; 95 % CI: 0.17-0.63; p = 0.567) of patients with AD, but did not affect their daily living activities (SMD: -0.10; 95 % CI: -0.31-0.12; p = 0.621). Physical training lasting from 16 to 24 weeks had a moderate effect only on the physical performance (SMD: 0.51; 95 % CI: 0.23-0.79; p = 0.000) of patients. Physical training for up to 12 weeks already leads to gains on the cognition, the physical performance and the quality of life of individuals with AD. Beyond the available evidence on health promotion resulting from physical training, guidelines should be established to define ideal training loads for patients with AD. Specific practical recommendations concerning the types, frequency, intensity or duration of physical exercise that may be the most efficient for ameliorating cognition, physical performance and quality of life of individuals with AD are still unclear.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":" ","pages":"102655"},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota in Alzheimer's disease: Understanding molecular pathways and potential therapeutic perspectives.","authors":"Simone Lista, Antonio Munafò, Filippo Caraci, Camillo Imbimbo, Enzo Emanuele, Piercarlo Minoretti, José Pinto-Fraga, María Merino-País, Paula Crespo-Escobar, Susana López-Ortiz, Giovanni Monteleone, Bruno P Imbimbo, Alejandro Santos-Lozano","doi":"10.1016/j.arr.2025.102659","DOIUrl":"10.1016/j.arr.2025.102659","url":null,"abstract":"<p><p>Accumulating evidence suggests that gut microbiota (GM) plays a crucial role in Alzheimer's disease (AD) pathogenesis and progression. This narrative review explores the complex interplay between GM, the immune system, and the central nervous system in AD. We discuss mechanisms through which GM dysbiosis can compromise intestinal barrier integrity, enabling pro-inflammatory molecules and metabolites to enter systemic circulation and the brain, potentially contributing to AD hallmarks. Additionally, we examine other pathophysiological mechanisms by which GM may influence AD risk, including the production of short-chain fatty acids, secondary bile acids, and tryptophan metabolites. The role of the vagus nerve in gut-brain communication is also addressed. We highlight potential therapeutic implications of targeting GM in AD, focusing on antibiotics, probiotics, prebiotics, postbiotics, phytochemicals, and fecal microbiota transplantation. While preclinical studies showed promise, clinical evidence remains limited and inconsistent. We critically assess clinical trials, emphasizing challenges in translating GM-based therapies to AD patients. The reviewed evidence underscores the need for further research to elucidate precise molecular mechanisms linking GM to AD and determine whether GM dysbiosis is a contributing factor or consequence of AD pathology. Future studies should focus on large-scale clinical trials to validate GM-based interventions' efficacy and safety in AD.</p>","PeriodicalId":93862,"journal":{"name":"Ageing research reviews","volume":" ","pages":"102659"},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}